Hypoparathyroidism in the news

This page displays the latest external news about hypoparathyroidism

  • Amolyt’s AZP-3601 Safely Normalizes Calcium Levels in Trial
    by Marisa Wexler, MS on September 19, 2022

    Treatment with AZP-3601, Amolyt Pharma’s experimental therapy for hypoparathyroidism, safely brought calcium levels to within normal ranges in the first group of patients in a Phase 2 clinical trial, the company has announced. Most of the trial participants were able to discontinue standard treatment with calcium and vitamin D supplements, and markers of bone health The post Amolyt’s AZP-3601 Safely Normalizes Calcium Levels in Trial appeared first on Hypoparathyroidism News.

  • Ascendis Seeks FDA Approval of TransCon PTH for Adults
    by Marisa Wexler, MS on September 12, 2022

    Ascendis Pharma has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of its treatment candidate TransCon PTH for adults with hypoparathyroidism, the company announced. “Our data support that TransCon PTH, if approved, could become the first-in-class therapy to address the underlying cause of disease and address the urgent needs of The post Ascendis Seeks FDA Approval of TransCon PTH for Adults appeared first on Hypoparathyroidism News.

  • Chronic Hypoparathryroidism Tied to Kidney Complications: Study
    by Margarida Maia, PhD on August 22, 2022

    Patients with long-lasting hypoparathyroidism in Sweden are over three times more likely than healthy individuals to develop kidney complications such as chronic kidney disease and kidney stones, and this may translate into more frequent hospital admissions, a study found. The study, “Kidney Complications and Hospitalization in Patients with Chronic Hypoparathyroidism: A Cohort Study in Sweden,” The post Chronic Hypoparathryroidism Tied to Kidney Complications: Study appeared first on Hypoparathyroidism News.

  • Low Calcium Found to Affect Certain Cognitive Functions Post-surgery
    by Lindsey Shapiro, PhD on August 15, 2022

    Patients with chronic hypoparathyroidism following surgery for thyroid cancer do not have overall significant cognitive impairments, but those with lower blood calcium levels showed some disruptions in cognitive function, according to a study. Specifically, patients with lower calcium levels exhibited impairments in visuo-spatial attention, semantic memory (memory of general knowledge), and executive function — a The post Low Calcium Found to Affect Certain Cognitive Functions Post-surgery appeared first on Hypoparathyroidism News.

  • Natpara May Help in Maintaining Heart Health, Trial Data Show
    by Marisa Wexler, MS on August 8, 2022

    Adults with hypoparathyroidism given long-term treatment with Natpara are less likely to experience heart-related health problems, according to an analysis of data from three clinical trials. Natpara “may confer cardiovascular benefits to patients with chronic hypoparathyroidism, and further research is warranted to understand the relationship better in a real-world setting,” the researchers wrote. The study, “Lower Risk of The post Natpara May Help in Maintaining Heart Health, Trial Data Show appeared first on Hypoparathyroidism News.

  • Hormone Replacement Therapy MBX 2109 Named FDA Orphan Drug
    by Marisa Wexler, MS on August 1, 2022

    MBX 2109, an experimental hormone replacement therapy that MBX Biosciences is developing for hypoparathyroidism, has been granted orphan drug status by the U.S. Food and Drug Administration (FDA). The FDA awards this designation to therapies intended to treat rare diseases, defined as those that affect less than 200,000 people in the U.S. It qualifies MBX, The post Hormone Replacement Therapy MBX 2109 Named FDA Orphan Drug appeared first on Hypoparathyroidism News.